<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="a resistant HCT8 colon carcinoma subline was developed by serial" exact="etoposide" post="exposure. Endoretroviral elements were detected by immunocytochemical staining, qPCR"/>
 <result pre="produce antitumoral effects. The introduction of antiviral drugs such as" exact="ribavirin" post="into the therapy of tumors with high HERV expression"/>
 <result pre="Ruhr-University of Bochum, Medical School. IC50 values and induction of" exact="etoposide" post="resistance IC50 values were determined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium"/>
 <result pre="nm. Both methods were formerly described [30, 31]. Resistance to" exact="etoposide" post="in HCT8 cells was induced in the same form"/>
 <result pre="and reported as the IC50 iCSCs/ IC50 parental ratio. Using" exact="etoposide" post="as chemoresistance-inducer it is feasible to induce a wide"/>
 <result pre="of antiviral and cytostatic drugs Amantadine, ribavirin, pleconaril, lamivudine, and" exact="doxorubicin" post="were purchased from Sigma-Aldrich, acyclovir and ganciclovir from HEXAL"/>
 <result pre="pleconaril, lamivudine, and doxorubicin were purchased from Sigma-Aldrich, acyclovir and" exact="ganciclovir" post="from HEXAL AG, Holzkirchen, Germany. Retrovir was obtained from"/>
 <result pre="Staffordshire, UK and brivudine from Berlin Chemie, Germany. Etoposide and" exact="cisplatin" post="were purchased from TEVA GmbH and 5FU from Medac,"/>
 <result pre="HERV proteins we exposure HCT8 cells to amantadine, pleconaril and" exact="ribavirin" post="alone or simultaneously at 1-fold their respective IC50-values for"/>
 <result pre="in medium containing the respective IC50 of amantadine, pleconaril, and" exact="ribavirin" post="alone or with all drugs simultaneously for 24 hours."/>
 <result pre="and HERV-FRD1 in HCT8RETO colorectal carcinoma cells The anticancer drug" exact="etoposide" post="is commonly not employed in the treatment of colorectal"/>
 <result pre="several tumors as previously described. In HCT8 colorectal carcinoma cells," exact="etoposide" post="induces characteristics for stemness, as judged by their self"/>
 <result pre="of antiproliferative effect, as defined by their IC50 values: amantadine," exact="ribavirin" post="and pleconaril (Fig. 4). All other drugs did not"/>
 <result pre="shown) and therefore were excluded from further analysis. In general," exact="amantadine" post="and pleconaril were the most active compounds in the"/>
 <result pre="cells (Fig. 4). Fig. 4 In vitro cytotoxicity of amantadine," exact="ribavirin" post="and pleconaril in HCT8WT/RETO cells. Cytotoxicity was measured over"/>
 <result pre="of at least n = 3 independent experiments Synergistic cytotoxic effects between" exact="amantadine" post="and anticancer drugs in HCT8WT/RETO cells We next questioned"/>
 <result pre="line (Fig. 5, panels a, c and e), interaction between" exact="amantadine" post="and doxorubicin was slightly synergistic (panel a), between amantadine"/>
 <result pre="5, panels a, c and e), interaction between amantadine and" exact="doxorubicin" post="was slightly synergistic (panel a), between amantadine and cisplatin"/>
 <result pre="between amantadine and doxorubicin was slightly synergistic (panel a), between" exact="amantadine" post="and cisplatin (CP) additive (panel c), and remarkable antagonistic"/>
 <result pre="and doxorubicin was slightly synergistic (panel a), between amantadine and" exact="cisplatin" post="(CP) additive (panel c), and remarkable antagonistic activity was"/>
 <result pre="additive (panel c), and remarkable antagonistic activity was observed between" exact="amantadine" post="and 5FU (panel e), respectively. In contrast, in the"/>
 <result pre="(Fig. 5, panels b, d and f), synergistic interaction between" exact="amantadine" post="and all three anticancer drugs was shown, although synergism"/>
 <result pre="(5FU) (panel f). These results indicate that antiviral compounds like" exact="amantadine" post="do not only exhibited substantial cytotoxic activity in chemoresistant"/>
 <result pre="vitro. Fig. 5 Isobologram showing the in vitro interaction between" exact="amantadine" post="and doxorubicin, cisplatin or 5FU in HCT8WT and HCT8RETO"/>
 <result pre="Isobologram showing the in vitro interaction between amantadine and doxorubicin," exact="cisplatin" post="or 5FU in HCT8WT and HCT8RETO cells. Dose-response curves"/>
 <result pre="by using their specific IC50. As expected, amantadine, pleconaril and" exact="ribavirin" post="as single drugs reduced cell survival by about 50"/>
 <result pre="%. Enhanced cytotoxicity in HCT8RETO cells was only detectable for" exact="amantadine" post="and pleconaril. In general, combination of antiviral compounds (Fig."/>
 <result pre="HCT8 colon carcinoma cells. Simultaneous incubation of HCT8WT/RETO with amantadine," exact="ribavirin" post="and pleconaril based on the IC50 values calculated for"/>
 <result pre="expressed different HERVs entities. We found that amantadine, pleconaril and" exact="ribavirin" post="alone or in combination applied simultaneously, significantly downregulated the"/>
 <result pre="upon exposure of chemo-resistant HCT8RETO cells to the antiviral compound" exact="amantadine" post="We have already shown enhanced cytotoxicity of antiviral compounds"/>
 <result pre="HCT8RETO cells in vitro (Fig. 4). Furthermore, we shown that" exact="amantadine" post="is able to reduce significantly the HERV protein expression"/>
 <result pre="c). Fig. 7 depicts the semi-quantification of the effect of" exact="amantadine" post="in HCT8WT/RETO cells as assayed by ELISA. As expected,"/>
 <result pre="the RNA levels (data not shown). Fig. 7 Effect of" exact="amantadine" post="on HERV protein expression in HCT8WT/RETO analyzed by ELISA."/>
 <result pre="of both HERV-WE1 and HERV-FRD1 is downregulated after incubation with" exact="amantadine" post="at 2 x IC50 for 24 hours. Expression is"/>
 <result pre="cancer cell lines. Among these compounds, the structurally unrelated amantadine," exact="ribavirin" post="and pleconaril were found to be the most active,"/>
 <result pre="phase of viral replication cycle. We focused our studies on" exact="amantadine" post="because we previously have been investigating several PPAP compounds"/>
 <result pre="promoters like Myc, Myb and Stat1/3 [44]. The combination of" exact="amantadine" post="with doxorubicin, cisplatin and 5FU acted synergistically in etoposide-refractory"/>
 <result pre="Myb and Stat1/3 [44]. The combination of amantadine with doxorubicin," exact="cisplatin" post="and 5FU acted synergistically in etoposide-refractory HCT8RETO, i.e. amantadine"/>
 <result pre="doxorubicin, cisplatin and 5FU acted synergistically in etoposide-refractory HCT8RETO, i.e." exact="amantadine" post="boosts the cytotoxicity of these cytostatics in resistant cells."/>
 <result pre="in resistant cells. We also addressed the combination of amantadine," exact="ribavirin" post="and pleconaril on overall cytotoxicity in HCT8WT/RETO cells. Enhanced"/>
 <result pre="Melanoma Tumor Growth In vivoCancer Res20056525889110.1158/0008-5472.CAN-04-423115805254 25.KraljacicBCArguelloMAmriACormackGBordenKInhibition of eIF4E with" exact="ribavirin" post="cooperates with common chemotherapies in primary acute myeloid leukemia"/>
 <result pre="proof-of-principle clinical trial with ribavirinBlood200911422576010.1182/blood-2009-02-20515319433856 29.AssoulineSCuljkovic-KraljacicBBergeronJCaplanSCocolakisELambertCA phase I trial of" exact="ribavirin" post="and low-dose cytarabine for the treatment of relapsed and"/>
 <result pre="with ribavirinBlood200911422576010.1182/blood-2009-02-20515319433856 29.AssoulineSCuljkovic-KraljacicBBergeronJCaplanSCocolakisELambertCA phase I trial of ribavirin and low-dose" exact="cytarabine" post="for the treatment of relapsed and refractory acute myeloid"/>
</results>
